Pemphigus Vulgaris (PV) Treatment Market Size, Share and Global Trend By Treatment Type (Corticosteroid, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy , Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Pemphigus Vulgaris (PV) is a potentially fatal autoimmune disease. It results in the development of painful blisters on the mucous membrane of the skin, mouth, throat, nose, or genitals. Pemphigus Vulgaris (PV) is rare in nature. According to the National Organisation of Rare Disorders, Pemphigus Vulgaris (PV) is estimated to affect 0.7-5 people per 1,000,000 population per year across the globe.
Pemphigus Vulgaris (PV) is caused when the immune system of the body starts attacking the proteins that are present on the skin. The rising prevalence of the disease and active government support has resulted in many clinical studies and increased research investment by pharmaceutical companies. For example, Cabaletta Bio is conducting clinical trails on DSG3-CAART, a type of cell therapy for mucosal Pemphigus Vulgaris (PV).
To gain extensive insights into the market, Request for Customization
Global Pemphigus Vulgaris (PV) treatment market growth is being driven by the rising prevalence of the Pemphigus Vulgaris (PV), increase in the research investment, and active government support. Also, increasing awareness regarding the disease, and presence of potential pipeline candidates are anticipated to further boost the global Pemphigus Vulgaris (PV) treatment market during the forecast period.
However, limited treatment options and side effects associated with the currently used non-biological drugs are the primary reasons that may hinder the growth in the global Pemphigus Vulgaris (PV) treatment market.
Key Players Covered
Some of the major companies that are present in the global Pemphigus Vulgaris (PV) Treatment market report are F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Genentech, Inc., Vifor Pharma Management Ltd., Alexion, and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Treatment Type | · Corticosteroid · Immunosuppressants · Biological Therapies · Intravenous Immunoglobulin (IVIG) Therapy · Others |
By Route of Administration | · Oral · Parenteral |
By Distribution Channel | · Hospital Pharmacy · Retail Pharmacy · Online Pharmacy |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
As per the current Pemphigus Vulgaris (PV) treatment market trends biological therapy segment, among the treatment type is anticipated to have a considerable growth owing to increasing demand for biological therapy for the treatment of diseases and reduced side effects.
Key Insights
- Prevalence of Pemphigus Vulgaris (PV) for key countries
- Regulatory scenario for key countries
- Pipeline Analysis
- Patent Analysis
- Recent industry developments such as partnerships, mergers, and acquisitions
Regional Analysis
The global Pemphigus Vulgaris (PV) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global Pemphigus Vulgaris (PV) treatment market over the forecast period owing to the rising prevalence of the Pemphigus Vulgaris (PV), increased R&D spending, and presence of potential pipeline candidates. The Pemphigus Vulgaris (PV) treatment market in Europe is estimated to expand due to the active government support. In March 2019, Roche, one of the prominent players in the pharmaceutical industry received European Commission approval for MabThera for treating adults with Pemphigus Vulgaris (PV), which is expected to increase the market size of Europe. Improving health reforms, increasing awareness and demand for biological products is anticipated to favor the market expansion in Aisa Pacific, Latin America, and the Middle East and Africa.
Pemphigus Vulgaris (PV) Treatment Industry Developments
- In March 2019, Roche, one of the prominent players in pharmaceutical industry received European Commission approval for MabThera for treating adults with Pemphigus Vulgaris (PV).
- In June 2018, Argenx released the interim data form the Phase 2 proof-of- concept clinical study of efgartigimod for treating Pemphigus Vulgaris (PV).
- Cabaletta Bio is conducting clinical trials on DSG3-CAART, a type of cell therapy for mucosal pemphigus vulgaris.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
